3SOF

Gaining momentum but looking at 3.39 as resistance to be broken first.
I wasn't sure if I should have started a new thread on this. When I did a search, there was none under stock picks.
I'm looking at gnvc as a momentum play for the day.
It was a pre-market mover, a new 52 week high, had a positive net price, trend is up in several time frames, but still waiting if the market makers are going to throw blocks at the ask and break that 3.39 pre-market high which could create a short squeeze. If not, then probably best to move on to another stock.

Chart looks nice.

GNVC on the move

Quote from: Terliso on April 08, 2007, 03:29:03 AM
Chart looks nice.

What a close with this nice chart stock.



5 Top Microcap Stocks

American Software (Nasdaq: AMSWA)
Northrim Bancorp (Nasdaq: NRIM)
GenVec (Nasdaq: GNVC)  Strong Buy
Aware (Nasdaq: AWRE)
Biosante Pharmaceuticals (AMEX: BPA)

Catch you up on the News.......


AP
GenVec Gets Payment From NIH Contract
Tuesday October 2, 10:43 am ET 
GenVec Receives $5.1 Million Payment As Part of 5-Year National Institutes of Health Contract


GAITHERSBURG, Md. (AP) -- Biotechnology company GenVec Inc. said Tuesday the National Institutes of Health executed its first option period under a five-year contract for vaccine production.
GenVec will receive $5.1 million for its second year of activity under the deal.

The previously announced five-year contract, with the NIH's National Institute of Allergy and Infectious Disease for vaccine production, is worth $52 million. The work includes the development of new HIV vaccine candidates.

Shares of GenVec rose 5 cents to $2.39 in morning trading. The stock has traded between $1.08 and $4.72 over the last 52 weeks.

Press Release Source: GenVec, Inc.


GenVec Named to Deloitte's Technology Fast 50 for Maryland
Wednesday October 3, 8:00 am ET


GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq: GNVC - News) has been named one of Maryland's fifty fastest growing technology, media, telecommunications and life science companies by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings in Deloitte's Technology Fast 50 Program are based on the percentage revenue growth over five years from 2002-2006. This year's Maryland Technology Fast 50 program is sponsored by WilmerHale, NASDAQ and SmartCEO.


"Maryland's Technology Fast 50 companies have shown the strength, vision and tenacity to succeed in today's very competitive technology environment," said Gary H. Tabach, Managing Partner of Deloitte's Greater Washington practice. "We applaud the successes of GenVec and acknowledge it as one of the very few to accomplish such a fast growth rate over the past five years."

Douglas J. Swirsky, GenVec's Chief Financial Officer attributes the company's revenue growth from 2002-2006 to increased demand for GenVec's technologies and expertise in adenovector design and production, and the company's success in expanding its scope of work on several current contracts. GenVec's multi-year, fully funded collaborations include the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the Naval Medical Research Center; the PATH Malaria Vaccine Initiative; the U.S. Department of Agriculture-Agricultural Research Service; and the U.S. Department of Homeland Security.

For the five-year period 2002-2006 GenVec's revenues increased 125%, ranking the company 37th in the Technology Fast 50 for Maryland.

"GenVec is honored to be recognized by Deloitte's Fast 50 Program. This award is a tribute to our outstanding employees whose energy and dedication have positioned our company among the leaders in this region," said Paul H. Fischer, GenVec's President and CEO.

To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2002 and $5,000,000 in 2006, be headquartered in Maryland, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM) is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte", "Deloitte & Touche", "Deloitte Touche Tohmatsu" or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.

Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services, LLP, Deloitte Tax LLP and their subsidiaries) and not by Deloitte & Touche USA LLP.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.


Contact:
GenVec, Inc.
Sharon L. Weinstein, 240-632-5511
Director, Investor Relations & Corporate Communications
[email protected]

--------------------------------------------------------------------------------
Source: GenVec, Inc.

Genvec has been in the news a lot for products being developed for cancer and for HIV vaccine research.
Genvec also has programs going to combat or produce vaccines for malaria (with the US Navy), macular degeneration, inner ear-related hearing loss, SARS, pandemic influenza's like bird flu and other ailments.
Their patented technology uses a cold virus component to inject therapeutic genetic material into target cells, promoting the desired response in the patient's body.
Genvec is working on antivirals and vaccine for foot and mouth disease in collaboration with the US Department of Agriculture research services. World-wide there is some concern over the threat of biological warfare targeting food supplies and foot and mouth would be a logical choice.


Technicals
Percentage Gainer

Last Price Quote is:
14.53%above 13-day MA
16.96%above 50-day MA
RS Rating: 94

Fundamentals
Key Data:
Market Cap (M): $180.12 
P/E Ratio: NA 
PEG Ratio: -0.262857 
Next Earnings: 11/07/2007
Last Analyst Rating: Buy

Ascending Triangle (Continuation) Pattern .......BreakOut !

looks very promising; I am invested

Nice La-Onda!

nice sumarization:
http://seekingalpha.com/instablog/401845-michael-catalin-vlaicu/26729-genvecs-tnferade-nears-nda-status-nasdaq-gnvc

nice chart:

 

GNVC: Roth Capital Starts @ Buy; Sets Tgt @ $4
Thursday , January 07, 2010 08:34ET
Issuer: GenVec, Incorporated (NasdaqNM: GNVC)
Analyst Firm:  Roth Capital Partners Inc.
Ratings Action: INITIATE
Current Rating: Buy
Target Price Action: INITIATE
Target Price: $4.00

Quote from: la-onda on November 25, 2009, 09:16:53 PM
looks very promising; I am invested

promising indeed...

Data from TNFerade(TM) Esophageal Cancer Study Presented at 2010 ASCO Gastrointestinal Cancer Symposium

GAITHERSBURG, Md., Jan. 22 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that data from the Company's trial in esophageal cancer were presented at the American Society of Clinical Oncology's 2010 Gastrointestinal Cancer Symposium in Orlando, Florida on January 22, 2010.

The poster, titled, "Long term survival analysis of multicenter clinical trial using endoscopy (END) and endoscopic ultrasound (EUS) guided fine needle injection (FNI) of antitumor agent (TNFerade Biologic (TNF)) in patients with locally advanced esophageal cancer," reports on updated efficacy and survival data. In the 24 patients receiving TNFerade in combination with chemoradiation, the median survival was 47.7 months.  Median survival from other historical clinical trials in similar stage disease ranged from 9.7 to 34 months.

Research presented in the poster received a prestigious ASCO Foundation Merit Award. In addition, the poster received focused attention at the oral review session on esophageal cancer on January 22, 2010.

"This symposium brings together the greatest thought leaders in this area of oncology and we are pleased to be presenting this analysis at this event," stated Mark Thornton, Ph.D., GenVec's Senior Vice President of Product Development. "The encouraging increases in survival versus historical controls will warrant additional evaluation."

The presented poster is available on GenVec's website, www.genvec.com. To view the poster, click on "Investor Relations" then "Webcasts and Data."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.


Investor Contact:
Media Contact:
 
GenVec, Inc.
Tiberend Strategic Advisors, Inc.
 
Danielle M. DiPirro
Andrew Mielach
 
(301) 944-1877
(212) 827-0020
 
[email protected]
[email protected]